Waters stock poised for gains as LCMS cycle boosts outlook, says Jefferies

On Tuesday, Jefferies elevated its position on Waters Corporation (NYSE:WAT) stock, a prominent analytical instrument manufacturer, from Hold to Buy. The firm also increased its price target for the company's shares to $415 from the previous $355.

This adjustment comes as a result of new insights from recent channel checks, which bolstered the firm's confidence in the commencement of the liquid chromatography-mass spectrometry (LCMS) replacement cycle.

The analyst at Jefferies noted that these replacement cycles typically lead to around a 300 basis points increase in performance. They highlighted that Waters Corp is well-positioned to capitalize on this cycle due to its updated product offerings, including the Alliance iS system.

The company is expected to benefit from various factors, such as its market mix, with a strong presence in Chinese generics and the Indian market, as well as emerging growth drivers like Good Laboratory Practices (GLPs) and analysis of per- and polyfluoroalkyl substances (PFAS).

Waters Corp's focus on its core competencies, without the distractions of other business segments like NASD or DGG, is another reason for the upgrade. The analyst expressed a preference for Waters Corp over its competitor Agilent (NYSE:A), which also holds a Hold rating, due to these strategic advantages.

The announcement of the upgrade and the new price target represents a significant increase in the anticipated value of Waters Corp's shares. The firm's revised outlook suggests a positive view of the company's market position and its potential for growth in the near term.

In other recent news, Waters Corporation has been the focus of several significant developments. The company's second-quarter earnings call revealed a resilient performance despite a continuous decline in sales.

Waters Corporation revised its full-year sales guidance for 2024 to a decline of -2% to -0.5%, with an adjusted operating margin of around 31%. The company's new product launches, such as the Xevo MRD and Acquity QDa II, have been positively received by customers, contributing to a cautiously optimistic outlook for the latter half of the year.

In addition to financial updates, Waters Corporation announced the appointment of Heather Knight to its Board of Directors. Knight, currently the Executive Vice President and Group President of Medical Products and Therapies at Baxter International (NYSE:BAX), brings nearly 30 years of experience in the pharmaceutical and medical device sectors. This strategic addition is expected to enhance the board's capabilities and align with Waters Corporation's objectives.

Analysts have also been closely following Waters Corporation. TD Cowen adjusted its outlook on the company following the second-quarter earnings call, raising its price target from $325 to $363 while maintaining a Hold rating on the stock.

This change reflects a positive shift in pharmaceutical spending and signs of broader recovery in the China market, despite the company's conservative guide for 2024. These are recent developments that investors in Waters Corporation may find noteworthy.

InvestingPro Insights

The recent upgrade by Jefferies aligns with several key metrics and insights from InvestingPro. Waters Corporation (NYSE:WAT) is currently trading near its 52-week high, with a strong return of 22.53% over the last three months. This performance supports Jefferies' optimistic outlook on the company's potential in the LCMS replacement cycle.

InvestingPro data shows that Waters has a market capitalization of $20.77 billion and a P/E ratio of 34.87, indicating that it's trading at a high earnings multiple. This valuation suggests that investors have high expectations for the company's future growth, which is consistent with Jefferies' bullish stance.

Two relevant InvestingPro Tips highlight that Waters operates with a moderate level of debt and that its liquid assets exceed short-term obligations. These factors contribute to the company's financial stability, potentially allowing it to invest in product development and capitalize on market opportunities like the LCMS replacement cycle mentioned in the article.

For investors seeking more comprehensive analysis, InvestingPro offers 11 additional tips for Waters Corporation, providing a deeper understanding of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.